Progenics PharmaceuticalsStock Price and Value Analysis

Should you buy Progenics Pharmaceuticals stock? (NasdaqGS:PGNX). Let's see how it does in our automated value investing analysis system.

AdvantagesDisadvantagesNeutral
  • This company is solid.
  • This stock looks overpriced.
  • This company has wild ups and downs.
  • This company is not making money.
  • This company pays no dividend.

PGNX Free Cash Flow Trend

Hmm, we can't give any reliable projection for Progenics Pharmaceuticals's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

Free Cash Flow trendline for PGNX
Free Cash Flow trendline for Progenics Pharmaceuticals

Inside the PGNX Numbers

PGNX Price
(Progenics Pharmaceuticals stock price per share)
$6.17
[?] PE Ratio versus Sector 264% higher than other Healthcare stocks
[?] PE Ratio versus Industry 27% higher than other Biotechnology stocks
[?] Cash Yield -9.25%
[?] Free Cash Flow Jitter 90%

Is Progenics Pharmaceuticals Stock on Sale?

Based on our analysis, we believe that you should not buy Progenics Pharmaceuticals right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy PGNX Stock?

Does Progenics Pharmaceuticals have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.